Stock listing
NASDAQ:DYN Dyne Therapeutics, Inc. Stock
Home listing (NASDAQ) of Dyne Therapeutics, Inc.
Follow Dyne Therapeutics, Inc. into a list and get an email when it puts out news.
Share price · NASDAQ:DYN
$15.50 USD -0.37 (-2.3%)
Close on Nov 20, 2026
- Day range
- $15.41 – $16.48 USDNov 20, 2026
- Volume
- 2.23M sharesNov 20, 2026
- Market cap
- $2.90B USDAt the close on Nov 20, 2026 · price × 187.4M shares outstanding
- 52-week range
- $14.00 – $27.31 USDLowest and highest trades, Nov 21, 2025 – Nov 20, 2026
- Traded on an average day
- $51.99M USDMedian day 2.53M shares · last 3 months, Aug 20, 2026 – Nov 20, 2026

Prices by listing
| Listing | Last | Change | Volume | Open | High | Low | Previous close | Price from |
|---|---|---|---|---|---|---|---|---|
| NASDAQ:DYN · Home | $15.50 USD | -0.37 (-2.3%) | 2,231,136 | $15.91 | $16.48 | $15.41 | $15.87 | Close on Nov 20, 2026 |
Daily closes
Last 3 months, Aug 20, 2026 – Nov 20, 2026 · NASDAQ:DYN · USD, adjusted for splits
| Day | Close | Change | % | Open | High | Low | Volume |
|---|---|---|---|---|---|---|---|
| $15.50 | -0.37 | -2.3% | $15.91 | $16.48 | $15.41 | 2,231,136 | |
| $15.87 | -0.15 | -0.9% | $15.92 | $16.56 | $15.87 | 2,927,669 | |
| $16.02 | -0.68 | -4.1% | $16.70 | $16.85 | $15.92 | 2,058,012 | |
| $16.70 | -0.46 | -2.7% | $16.92 | $17.24 | $16.49 | 1,849,636 | |
| $17.16 | +0.15 | +0.9% | $16.90 | $17.35 | $16.42 | 1,674,293 | |
| $17.01 | -0.98 | -5.4% | $17.70 | $17.78 | $17.01 | 2,311,962 | |
| $17.99 | +0.07 | +0.4% | $18.10 | $18.31 | $17.85 | 1,909,757 | |
| $17.92 | -0.70 | -3.8% | $18.29 | $18.64 | $17.33 | 2,392,553 | |
| $18.62 | +0.55 | +3.0% | $18.51 | $19.00 | $17.89 | 3,860,440 | |
| $18.07 | +0.71 | +4.1% | $17.68 | $18.33 | $17.40 | 2,359,185 | |
| $17.36 | -1.18 | -6.4% | $18.78 | $18.78 | $17.33 | 3,203,978 | |
| $18.54 | +0.49 | +2.7% | $18.57 | $19.00 | $17.94 | 3,649,277 | |
| $18.05 | +0.75 | +4.3% | $17.53 | $18.15 | $17.32 | 2,815,818 | |
| $17.30 | +0.61 | +3.7% | $16.81 | $17.35 | $16.71 | 2,907,337 | |
| $16.69 | -0.35 | -2.1% | $17.04 | $17.19 | $16.34 | 1,449,801 | |
| $17.04 | +0.06 | +0.4% | $17.20 | $17.59 | $16.75 | 1,427,300 | |
| $16.98 | +0.04 | +0.2% | $16.30 | $17.12 | $16.11 | 2,177,500 | |
| $16.94 | +1.22 | +7.8% | $15.80 | $16.97 | $15.73 | 3,002,000 | |
| $15.72 | +0.10 | +0.6% | $15.64 | $16.02 | $15.53 | 1,741,900 | |
| $15.62 | -0.15 | -1.0% | $15.92 | $15.92 | $15.32 | 2,134,300 | |
| $15.77 | -0.30 | -1.9% | $15.99 | $16.34 | $15.67 | 2,052,500 | |
| $16.07 | -0.20 | -1.2% | $16.33 | $16.73 | $15.91 | 1,789,800 | |
| $16.27 | +1.04 | +6.8% | $15.27 | $16.56 | $15.14 | 3,405,300 | |
| $15.23 | +0.98 | +6.9% | $14.45 | $15.38 | $14.45 | 3,346,200 | |
| $14.25 | -1.04 | -6.8% | $15.21 | $15.49 | $14.13 | 2,860,500 | |
| $15.29 | +0.25 | +1.7% | $15.15 | $15.47 | $15.04 | 2,074,600 | |
| $15.04 | -0.26 | -1.7% | $15.11 | $15.42 | $14.71 | 2,195,900 | |
| $15.30 | -0.66 | -4.1% | $15.97 | $15.99 | $15.28 | 3,341,600 | |
| $15.96 | -0.68 | -4.1% | $16.54 | $16.76 | $15.73 | 2,915,100 | |
| $16.64 | +0.27 | +1.6% | $16.41 | $17.31 | $16.36 | 3,565,900 | |
| $16.37 | +0.40 | +2.5% | $15.84 | $16.47 | $15.35 | 6,279,500 | |
| $15.97 | +0.57 | +3.7% | $15.40 | $16.12 | $15.25 | 3,489,900 | |
| $15.40 | -0.04 | -0.3% | $15.50 | $15.59 | $14.93 | 4,098,700 | |
| $15.44 | +0.24 | +1.6% | $15.31 | $15.54 | $15.08 | 4,377,300 | |
| $15.20 | -0.62 | -3.9% | $16.03 | $16.03 | $15.09 | 2,534,100 | |
| $15.82 | -0.29 | -1.8% | $16.01 | $16.28 | $15.52 | 3,699,400 | |
| $16.11 | -0.10 | -0.6% | $16.05 | $16.80 | $15.92 | 4,456,500 | |
| $16.21 | -0.13 | -0.8% | $16.40 | $16.55 | $15.97 | 2,287,000 | |
| $16.34 | +0.31 | +1.9% | $15.86 | $16.43 | $15.63 | 2,305,800 | |
| $16.03 | -0.48 | -2.9% | $16.62 | $16.76 | $16.02 | 1,612,100 | |
| $16.51 | +0.28 | +1.7% | $16.09 | $16.65 | $15.88 | 3,197,700 | |
| $16.23 | -0.91 | -5.3% | $17.08 | $17.08 | $16.18 | 2,636,200 | |
| $17.14 | +0.02 | +0.1% | $17.39 | $17.59 | $17.06 | 2,627,000 | |
| $17.12 | +0.01 | +0.1% | $17.31 | $17.59 | $16.75 | 3,219,800 | |
| $17.11 | -0.95 | -5.3% | $18.07 | $18.15 | $16.96 | 4,849,100 | |
| $18.06 | +0.755 | +4.4% | $17.90 | $18.11 | $17.62 | 2,846,800 | |
| $17.31 | -0.595 | -3.3% | $18.37 | $18.37 | $17.09 | 2,156,000 | |
| $17.90 | -0.62 | -3.3% | $18.52 | $18.62 | $17.87 | 3,029,200 | |
| $18.52 | +0.31 | +1.7% | $18.40 | $19.15 | $18.27 | 3,196,900 | |
| $18.21 | -0.21 | -1.1% | $18.59 | $18.74 | $17.94 | 3,774,300 | |
| $18.42 | -0.77 | -4.0% | $19.03 | $19.03 | $17.93 | 4,709,500 | |
| $19.19 | -1.12 | -5.5% | $19.38 | $20.16 | $18.97 | 5,143,000 | |
| $20.31 | -3.97 | -16.4% | $17.08 | $20.91 | $17.00 | 17,173,100 | |
| $24.28 | -0.67 | -2.7% | $24.59 | $24.70 | $24.14 | 1,588,000 | |
| $24.95 | -0.19 | -0.8% | $25.26 | $25.39 | $24.60 | 1,453,500 | |
| $25.14 | +0.04 | +0.2% | $25.55 | $26.18 | $24.92 | 2,180,600 | |
| $25.10 | -0.33 | -1.3% | $24.99 | $25.40 | $24.72 | 1,629,400 | |
| $25.43 | +0.36 | +1.4% | $24.92 | $25.65 | $24.58 | 2,769,300 | |
| $25.07 | -1.02 | -3.9% | $25.82 | $25.98 | $24.83 | 1,186,900 | |
| $26.09 | -0.27 | -1.0% | $26.29 | $26.49 | $25.98 | 1,018,700 | |
| $26.36 | +0.02 | +0.1% | $26.32 | $26.47 | $25.78 | 1,527,800 | |
| $26.34 | +0.35 | +1.3% | $26.28 | $26.69 | $25.97 | 1,459,196 | |
| $25.99 | -0.11 | -0.4% | $26.13 | $26.14 | $25.14 | 1,370,092 | |
| $26.10 | +0.12 | +0.5% | $26.22 | $26.87 | $26.02 | 1,181,800 | |
| $25.98 | -0.80 | -3.0% | $26.33 | $26.43 | $25.68 | 1,484,300 |
- Ticker
- NASDAQ:DYN
- Asset type
- Stock
- Sector
- Health care
- Industry
- Biotechnology
- Exchange
- NASDAQ
- Currency
- USD
What changed lately
Latest news release · Nov 19, 2026
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Latest deck · Sep 29, 2026
World Muscle Society 31st Annual Congress 2026
Conference · 22 slides
Latest news
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Nov 19, 2026
Closed $15.50 (-2.3%) on Nov 20, 2026
Dyne Therapeutics to Participate in Upcoming Investor Conference
Nov 11, 2026
Closed $17.99 (+0.4%) on Nov 11, 2026
Dyne Therapeutics Reports Third Quarter 2026 Financial Results and Recent Business Highlights
Nov 5, 2026
Closed $17.36 (-6.4%) on Nov 5, 2026
Dyne Therapeutics Announces Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1)
Sep 29, 2026
Closed $16.11 (-0.6%) on Sep 30, 2026
Dyne Therapeutics to Present Additional One-Year Clinical Data from Phase 1/2 ACHIEVE Trial of Z-Basivarsen (DYNE-101) for Myotonic Dystrophy Type 1 (DM1) at Upcoming Medical Meetings
Sep 8, 2026
Closed $20.31 (-16.4%) on Sep 8, 2026
Dyne Therapeutics to Present Preclinical Data for Multiple Development Candidates for Duchenne Muscular Dystrophy (DMD) at 27th Annual NMSG Scientific Meeting
Sep 3, 2026
Closed $24.95 (-0.8%) on Sep 3, 2026
Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlights
Jul 29, 2026
Closed $25.73 (+2.5%) on Jul 30, 2026
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)
Jul 28, 2026
Closed $25.90 (+1.1%) on Jul 28, 2026
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stock
Jul 21, 2026
Closed $23.21 (-2.6%) on Jul 22, 2026
Dyne Therapeutics, Inc. on 6ix
- Sector
- Health care
- Industry
- Biotechnology
- News releases
- 34 in the last 12 months · 146 in all · newest Nov 19, 2026 · oldest 2020
- Decks
- 15 decks · latest Sep 29, 2026
Where Dyne Therapeutics, Inc. is listed
| Listing | Exchange | Country | Currency |
|---|---|---|---|
| NASDAQ:DYN · Home listing · This page | NASDAQ | United States | USD |
| BOATS:DYN | BOATS | United States | USD |
| BX Swiss:DYN | BX Swiss | Switzerland | CHF |
Valuation
Price/book 3.1× against a median of 3.9×: 3rd lowest of 10 Biotechnology companies shown. Statements: 4 quarters to Sep 30, 2026 · price Nov 20, 2026
- Enterprise value
- $1.97B USD
- P/E
- Loss
- EV/sales
- No revenue
- EV/EBITDA
- Negative EBITDA
- Price/book
- 3.1×
- Gross margin
- No revenue
- Operating margin
- No revenue
- Net margin
- No revenue
- Debt to equity
- 0.2×
- Beta vs S&P 500
- 1.51
Biotechnology: the 10 companies nearest in size, of 890 on 6ix with figures. Size in US dollars.
| Company | Mkt cap | EV | P/E | EV/Sales | EV/EBITDA | P/B | Net mgn | Debt/Eq | Beta |
|---|---|---|---|---|---|---|---|---|---|
| Dyne Therapeutics, Inc. · NASDAQ:DYN | US$2.90B | US$1.97B | n/a | n/a | n/a | 3.1× | n/a | 0.2× | 1.51 |
| Iovance Biotherapeutics, Inc. · NASDAQ:IOVA | US$3.19B | US$2.86B | n/a | 7.5× | n/a | 3.9× | −58.2% | 0.1× | 1.62 |
| AbCellera Biologics Inc. · NASDAQ:ABCL | US$3.16B | US$2.53B | n/a | 37.3× | n/a | 3.0× | −218.5% | 0.1× | 2.42 |
| Viking Therapeutics, Inc. · NASDAQ:VKTX | US$3.16B | US$2.20B | n/a | n/a | n/a | 5.4× | n/a | 0.0× | 1.31 |
| Lin BioScience, Inc. · TPEX:6696 | US$3.01B | US$2.50B | n/a | n/a | n/a | 9.3× | n/a | 0.0× | n/a |
| Legend Biotech Corp. · NASDAQ:LEGN | US$2.97B | US$2.28B | n/a | 1.7× | 27.0× | 2.3× | −0.0% | 0.1× | 0.75 |
| Denali Therapeutics Inc. · NASDAQ:DNLI | US$2.96B | US$2.69B | n/a | 126× | n/a | 3.2× | n/a | 0.3× | 1.30 |
| Shanghai Junshi Biosciences Co., Ltd. Class A · SSE:688180 | US$2.88B | US$2.99B | n/a | 8.0× | n/a | 3.2× | −35.0% | 0.7× | n/a |
| SELLAS Life Sciences Group, Inc. · NASDAQ:SLS | US$2.78B | US$2.65B | n/a | n/a | n/a | 21.1× | n/a | 0.0× | 2.19 |
| HLB Co., Ltd. · KRX:028300 | US$2.69B | US$2.69B | n/a | 36.9× | n/a | 10.4× | −219.1% | 0.2× | n/a |
| Celcuity Inc. · NASDAQ:CELC | US$2.62B | US$1.98B | n/a | n/a | n/a | n/a | n/a | n/a | 1.10 |
| Median of the others | US$2.96B | US$2.59B | 22.4× | 27.0× | 3.9× | −58.2% | 0.1× | 1.31 |
Forecasts
12 strong buy · 3 buy · 1 hold · 1 sell · Analysts' consensus from EODHD, read Nov 20, 2026. Not 6ix's view and not investment advice.
- Price target
- 34.33 USD · Analysts' mean
- EPS, year to Dec 2026
- -3.89 · 10 analysts
Team and board
Officers
| Officer | Role |
|---|---|
| John Cox | President and Chief Executive Officer |
| Erick J. Lucera | Chief Financial Officer |
| Alessandro Martuscelli | Chief Legal Officer |
| Axel Wiest | Senior Vice President, Head of Portfolio Strategy & Operations |
| Debra Feldman | Chief Regulatory Affairs Officer |
| Doug Kerr | Head of Research & Development and Chief Medical Officer |
| James P. Bilotta | Chief Digital Information Officer |
| Johanna Friedl-Naderer | Chief Commercial Officer |
| José Juves | Chief Corporate & Patient Affairs Officer |
| Lucia Celona | Chief Human Resources Officer |
| Monica Fay | Chief Medical Affairs Officer |
| Oxana Beskrovnaya | Chief Innovation Officer |
| Raj Manchanda | Chief Technical Officer |
| Ranjan Batra | Chief Scientific Officer |
| Vikram Ranade | Chief Business Officer |
Board
| Director | Role |
|---|---|
| Jason Rhodes | Chairman |
| Alessandro Martuscelli | Chief Legal Officer |
| Axel Wiest | Senior Vice President, Head of Portfolio Strategy & Operations |
| Barry Greene | Board Member |
| Brian Posner | Board Member |
| Carlo Incerti | Board Member |
| Catherine Stehman-Breen | Board Member |
| David Lubner | Board Member |
| Debra Feldman | Chief Regulatory Affairs Officer |
| Dirk Kersten | Board Member |
| Ed Hurwitz | Board Member |
| Erick J. Lucera | Chief Financial Officer |
| James P. Bilotta | Chief Digital Information Officer |
| Johanna Friedl-Naderer | Chief Commercial Officer |
| John Cox | President and Chief Executive Officer |
| José Juves | Chief Corporate & Patient Affairs Officer |
| Lucia Celona | Chief Human Resources Officer |
| Monica Fay | Chief Medical Affairs Officer |
| Oxana Beskrovnaya | Chief Innovation Officer |
| Raj Manchanda | Chief Technical Officer |
| Ranjan Batra | Chief Scientific Officer |
| Vikram Karnani | Board Member |
| Vikram Ranade | Chief Business Officer |
Events
| Quarter | Results | Share move |
|---|---|---|
| Q3 2026 | Nov 5, 2026 · Before open | −6.4% |
| Q2 2026 | Jul 29, 2026 · After close | +2.5% |
| Q1 2026 | May 11, 2026 · Before open | +4.8% |
| Q4 2025 | Feb 26, 2026 | −2.9% |
| Q3 2025 | Nov 5, 2025 · After close | −12.9% |
| Q2 2025 | Jul 28, 2025 · After close | −1.2% |
| Q1 2025 | May 8, 2025 · Before open | +20.2% |
| Q4 2024 | Mar 3, 2025 · Before open | −9.5% |
| Q3 2024 | Nov 12, 2024 · Before open | +4.3% |
| Q2 2024 | Aug 12, 2024 · After close | +1.3% |
All 20 quarters
| Quarter | Results | Share move |
|---|---|---|
| Q1 2024 | May 2, 2024 · After close | +0.3% |
| Q4 2023 | Mar 5, 2024 · Before open | −6.6% |
| Q3 2023 | Oct 30, 2023 · Before open | +10.6% |
| Q2 2023 | Aug 3, 2023 · Before open | −2.2% |
| Q1 2023 | May 11, 2023 · Before open | −2.8% |
| Q4 2022 | Mar 2, 2023 · Before open | +5.1% |
| Q3 2022 | Nov 3, 2022 · Before open | +9.6% |
| Q2 2022 | Aug 4, 2022 · Before open | +3.1% |
| Q1 2022 | May 2, 2022 · After close | +3.5% |
| Q4 2021 | Mar 10, 2022 · Before open | +1.2% |
Decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| World Muscle Society 31st Annual Congress 2026 | Conference | 22 slides | Sep 29, 2026 |
| RNA Leaders US 2026 | Conference | 19 slides | Sep 25, 2026 |
| 44th Annual J.P. Morgan Healthcare Conference 2026 | Conference | 31 slides | Jan 12, 2026 |
| Technical Presentation (2026) | Technical | 17 slides | 2026 |
| Corporate Update (December 2025) | Corporate update | 34 slides | Dec 8, 2025 |
| Corporate Update (June 2025) | Corporate update | 29 slides | Jun 17, 2025 |
| Corporate Update (January 2025) | Corporate update | 43 slides | Jan 10, 2025 |
| Technical Presentation (September 2024) | Technical | 26 slides | Sep 3, 2024 |
| Corporate Update (May 2024) | Corporate update | 47 slides | May 20, 2024 |
| 2024 AAN Annual Meeting | Conference | 11 slides | Apr 15, 2024 |
All 15 decks
| Deck | Kind | Slides | Date |
|---|---|---|---|
| AAN Annual Meeting 2023 | Conference | 8 slides | Apr 25, 2023 |
| American Society of Gene & Cell Therapy 2022 | Conference | 15 slides | May 16, 2022 |
| Muscle Study Group Annual Scientific Meeting 2021 | Conference | 29 slides | Nov 4, 2021 |
| FSHD IRC 2021 | Conference | 11 slides | Jun 25, 2021 |
| ASGCT Annual Meeting 2021 | Conference | 19 slides | May 14, 2021 |
Financings
| Raise | Date |
|---|---|
| Public offering of common stock Made bigger: US$375.15M · US$20.5 a share · Morgan Stanley +5 Dealers: Morgan Stanley (co-lead), Jefferies (co-lead), Evercore ISI (co-lead), LifeSci Capital (co-lead), Raymond James (co-lead), Jones | Jul 22, 2026 |
| Public offering of common stock Closed: US$402.5M raised · US$18.44 a share · Morgan Stanley +3 Dealers: Morgan Stanley (co-lead), Jefferies (co-lead), Stifel (co-lead), Guggenheim Securities (co-lead) | Dec 11, 2025 |
| Public offering of common stock Closed: US$230M raised · US$8.25 a share · Morgan Stanley +4 Dealers: Morgan Stanley (co-lead), Jefferies (co-lead), Stifel (co-lead), Guggenheim Securities (co-lead), Jones | Jul 2, 2025 |
| At-the-market programme of common stock Closed: US$140.6M raised Use of proceeds: To fund operations, together with existing cash, at least into the second half of 2026 | Feb 27, 2025 |
Open Financings · Read by 6ix AI from the company's releases
IPO
Priced at US$19.00 a share on Sep 16, 2020.
- Price
- US$19.00 a share
- Shares offered
- 12,251,578 shares of common stock
- Offering size
- US$232.8 million
- Underwriters' option
- Up to 1,837,736 more shares
- Underwriters
- J.P. Morgan, Jefferies, Piper Sandler, Stifel · In the order on the cover
- Shares delivered
- On or about Sep 21, 2020
Steps
| Step | When |
|---|---|
| Draft sent to the SEC in confidence | Jul 23, 2020 |
| Filed publicly | Aug 25, 2020 |
| Amended once | Sep 10, 2020 |
| Shares registered with an exchange | Sep 11, 2020 |
| Declared effective by the SEC | Sep 16, 2020 |
| Final prospectus, with the price | Sep 17, 2020 |
Filings
| Filing | Filed |
|---|---|
| 424B4 · Prospectus | Sep 17, 2020 |
| EFFECT · Notice that a registration is effective | Sep 16, 2020 |
| S-1MEF · Registration of more shares for the same offering | Sep 16, 2020 |
| CERT · Exchange's certificate of listing | Sep 16, 2020 |
| CORRESP · Letter to the SEC | Sep 14, 2020 |
| CORRESP · Letter to the SEC | Sep 14, 2020 |
| 8-A12B · Registration of shares for listing on an exchange | Sep 11, 2020 |
| UPLOAD · Letter from the SEC | Sep 10, 2020 |
| CORRESP · Letter to the SEC | Sep 10, 2020 |
| S-1/A · Registration statement, amended | Sep 10, 2020 |
All 14 filings
| Filing | Filed |
|---|---|
| CORRESP · Letter to the SEC | Aug 25, 2020 |
| S-1 · Registration statement | Aug 25, 2020 |
| UPLOAD · Letter from the SEC | Aug 20, 2020 |
| DRS · Draft registration statement | Jul 23, 2020 |
Open IPO · From the cover of the final prospectus (424B4) filed Sep 17, 2020
Financials
Annual, in USD
Income statement
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 506.0M | 1.37B |
| Cost of revenue | 2.05M | 2.24M | 2.46M | 3.35M | 1.09M | 700.0K | 271.0K | 24.0K | 2.93B | 2.28B |
| Gross profit | -2.05M | -2.24M | -2.46M | -3.35M | -1.09M | -700.0K | -271.0K | -24.0K | -2.43B | -915.0M |
| Research and development | 398.3M | 281.4M | 210.8M | 142.8M | 121.3M | 45.2M | 11.0M | 4.28M | ||
| Selling, general and administrative | 69.9M | 62.5M | 31.4M | 28.2M | 28.7M | 13.4M | 2.79M | 517.0K | 189.0M | 161.0M |
| Operating income | -468.2M | -343.9M | -242.2M | -171.0M | -150.0M | -58.6M | -13.8M | -4.79M | -412.0M | -640.0M |
| Depreciation and amortization | 2.05M | 1.67M | 1.67M | 1.68M | 1.09M | 700.0K | 271.0K | 24.0K | 867.0M | 766.0M |
| EBITDA | -466.1M | -342.2M | -240.5M | -169.3M | -148.9M | -57.9M | -13.6M | -4.77M | 455.0M | 126.0M |
| Interest expense | 6.19M | 0 | 0 | 2.92M | 742.0K | 396.0K | 290.0K | 5.00K | 616.0M | 625.0M |
| Income before tax | -446.2M | -317.4M | -235.9M | -168.1M | -149.3M | -59.4M | -14.9M | -4.81M | -538.0M | -1.29B |
| Income tax | 0 | 0 | 0 | -2.86M | -8.00K | -700.0K | -1.32M | -11.0K | -610.0M | -45.0M |
| Net income | -446.2M | -317.4M | -235.9M | -168.1M | -149.3M | -59.4M | -14.9M | -4.81M | 76.0M | -1.24B |
| Earnings per share, basic | -3.47 | -3.37 | -3.95 | -3.23 | -2.93 | -4.13 | -6.08 | -0.47 | 0.47 | -9.61 |
| Earnings per share, diluted | -3.47 | -3.37 | -3.95 | -3.23 | -2.93 | -4.13 | -6.08 |
Balance sheet
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | 893.4M | 435.4M | 121.6M | 172.1M | 200.8M | 300.9M | 14.6M | 8.12M | 365.0M | 1.78B |
| Short-term investments | 217.2M | 206.8M | 1.47M | 83.9M | 175.7M | 44.5M | 0 | 32.0M | 130.0M | |
| Receivables | 513.0M | 386.0M | ||||||||
| Inventory | 445.0M | 445.0M | ||||||||
| Current assets | 1.13B | 659.3M | 129.4M | 265.6M | 382.4M | 349.1M | 14.8M | 8.16M | 1.52B | 2.99B |
| Property, plant and equipment | 24.0M | 5.40M | 4.78M | 5.95M | 4.68M | 1.95M | 1.49M | 110.0K | ||
| Goodwill | 772.0M | 799.0M | ||||||||
| Total assets | 1.19B | 691.2M | 165.1M | 306.3M | 425.7M | 353.3M | 16.4M | 8.27M | 11.8B | 13.1B |
| Accounts payable | 8.08M | 6.56M | 22.9M | 5.26M | 4.03M | 3.44M | 1.26M | 518.0K | 367.0M | 332.0M |
| Current liabilities | 50.6M | 42.3M | 51.1M | 28.1M | 28.7M | 11.0M | 2.36M | 711.0K | 1.05B | 916.0M |
| Long-term debt | 148.9M | |||||||||
| Total debt | 148.9M | 0 | 27.4M | 30.5M | 32.6M | 3.38M | 8.43B | 8.98B | ||
| Total liabilities | 214.8M | 61.4M | 73.8M | 54.0M | 57.5M | 11.0M | 2.40M | 13.1M | 9.87B | 11.0B |
| Shareholders' equity | 972.1M | 629.8M | 91.3M | 252.4M | 368.2M | 342.4M | 14.0M | -4.88M | 1.90B | 2.04B |
| Shares outstanding | 165.0M | 102.3M | 61.5M | 55.6M | 51.6M | 45.1M | 2.59M | 10.3M | 162.0M | 129.0M |
Cash flow
| Line | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | -403.2M | -292.4M | -188.2M | -153.6M | -119.6M | -46.5M | -11.8M | -4.16M | 585.0M | 676.0M |
| Capital spending | -1.92M | -2.38M | -729.0K | -3.07M | -3.62M | -1.16M | -1.65M | -134.0K | -224.0M | -326.0M |
| Free cash flow | -405.1M | -294.7M | -188.9M | -156.7M | -123.2M | -47.7M | -13.5M | -4.30M | 361.0M | 350.0M |
| Cash from investing | -28.8M | -204.1M | 83.3M | 87.2M | -137.9M | -45.7M | -1.65M | -134.0K | -2.76B | -2.15B |
| Cash from financing | 890.3M | 809.9M | 54.3M | 37.4M | 157.8M | 380.7M | 20.0M | 12.4M | -1.30B | 2.74B |
| Dividends paid | -22.0M | -22.0M | ||||||||
| Share buybacks | 20.0M | 7.42M | ||||||||
| Change in cash | 458.3M | 313.4M | -50.5M | -29.1M | -99.6M | 288.5M | 6.51M | 12.4M | -3.47B | 1.27B |
Filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Nov 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 16, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Nov 16, 2026 | Insider trade | SEC |
| SCHEDULE 13G · Big-stake notice | Nov 16, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Nov 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Nov 13, 2026 | Other filings | SEC |
| 8-K · Current report | Nov 5, 2026 | Results | SEC |
| 10-Q · Quarterly report | Nov 5, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | Oct 22, 2026 | Insider trade | SEC |
Show 200 filings
| Filing | Date | Type | Filed with |
|---|---|---|---|
| 4 · Change in ownership | Oct 6, 2026 | Insider trade | SEC |
| 8-K · Current report | Sep 29, 2026 | Current report | SEC |
| 144 · Notice of proposed sale | Sep 8, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Sep 8, 2026 | Other filings | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Sep 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Sep 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | Aug 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Aug 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Aug 14, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 14, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 14, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Aug 13, 2026 | Other filings | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 13, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Aug 6, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jul 29, 2026 | Results | SEC |
| 4 · Change in ownership | Jul 29, 2026 | Insider trade | SEC |
| 10-Q · Quarterly report | Jul 29, 2026 | Quarterly report | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Jul 28, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Jul 27, 2026 | Other filings | SEC |
| 424B5 · Prospectus | Jul 22, 2026 | Offer document | SEC |
| 8-K · Current report | Jul 22, 2026 | Material contract | SEC |
| 424B5 · Prospectus | Jul 21, 2026 | Offer document | SEC |
| 8-K · Current report | Jul 20, 2026 | Current report | SEC |
| 4 · Change in ownership | Jul 8, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jul 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 7, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jul 6, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 30, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 29, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 29, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 29, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 26, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 26, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 26, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 26, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 25, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 25, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 25, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 25, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 24, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 24, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 24, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 24, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Jun 23, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 23, 2026 | Insider trade | SEC |
| 3 · Initial statement of ownership | Jun 23, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 22, 2026 | Management or board change | SEC |
| 4 · Change in ownership | Jun 22, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 17, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Jun 17, 2026 | Other filings | SEC |
| 8-K · Current report | Jun 17, 2026 | Material contract | SEC |
| 144 · Notice of proposed sale | Jun 16, 2026 | Other filings | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Jun 9, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 8, 2026 | Meeting outcome | SEC |
| 4 · Change in ownership | Jun 5, 2026 | Insider trade | SEC |
| 8-K · Current report | Jun 3, 2026 | Current report | SEC |
| 4 · Change in ownership | May 28, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 22, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | May 15, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 4 · Change in ownership | May 14, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 13, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 13, 2026 | Other filings | SEC |
| 8-K · Current report | May 11, 2026 | Results | SEC |
| 10-Q · Quarterly report | May 11, 2026 | Quarterly report | SEC |
| 4 · Change in ownership | May 6, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | May 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 6, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 6, 2026 | Other filings | SEC |
| SCHEDULE 13G · Big-stake notice | May 6, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | May 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 5, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 4, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | May 4, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 30, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 28, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 28, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 28, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 28, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 28, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 27, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 27, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 27, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 27, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 27, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 24, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 24, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 24, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 24, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 23, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 23, 2026 | Other filings | SEC |
| ARS · Annual report to shareholders | Apr 23, 2026 | Annual report | SEC |
| 4 · Change in ownership | Apr 23, 2026 | Insider trade | SEC |
| DEFA14A · Additional proxy material | Apr 23, 2026 | Meeting notice | SEC |
| DEF 14A · Proxy statement | Apr 23, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 22, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 22, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 22, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 22, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 22, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 21, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 21, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 21, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 21, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 21, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 20, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 20, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 20, 2026 | Other filings | SEC |
| 144 · Notice of proposed sale | Apr 20, 2026 | Other filings | SEC |
| 4 · Change in ownership | Apr 17, 2026 | Insider trade | SEC |
| PRE 14A · Preliminary proxy statement | Apr 9, 2026 | Meeting notice | SEC |
| 4 · Change in ownership | Apr 3, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Apr 1, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Apr 1, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Mar 27, 2026 | Offer document | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 26, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 13, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 11, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 11, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 10, 2026 | Insider trade | SEC |
| 144 · Notice of proposed sale | Mar 9, 2026 | Other filings | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Mar 6, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Mar 6, 2026 | Big-stake notice | SEC |
| 144 · Notice of proposed sale | Mar 5, 2026 | Other filings | SEC |
| S-8 · Registration statement for employee plans | Mar 2, 2026 | Offer document | SEC |
| 8-K · Current report | Mar 2, 2026 | Results | SEC |
| 10-K · Annual report | Mar 2, 2026 | Annual report | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| 4 · Change in ownership | Feb 17, 2026 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Feb 17, 2026 | Big-stake notice | SEC |
| 8-K · Current report | Jan 12, 2026 | Results | SEC |
| SCHEDULE 13G · Big-stake notice | Jan 8, 2026 | Big-stake notice | SEC |
| 4 · Change in ownership | Dec 23, 2025 | Insider trade | SEC |
| 3 · Initial statement of ownership | Dec 23, 2025 | Insider trade | SEC |
| 8-K · Current report | Dec 23, 2025 | Management or board change | SEC |
| 424B5 · Prospectus | Dec 10, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 10, 2025 | Material contract | SEC |
| 424B5 · Prospectus | Dec 8, 2025 | Offer document | SEC |
| 8-K · Current report | Dec 8, 2025 | Financing | SEC |
| 8-K · Current report | Dec 8, 2025 | Current report | SEC |
| 144 · Notice of proposed sale | Dec 5, 2025 | Other filings | SEC |
| 144 · Notice of proposed sale | Dec 5, 2025 | Other filings | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| 4 · Change in ownership | Dec 5, 2025 | Insider trade | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 14, 2025 | Big-stake notice | SEC |
| SCHEDULE 13G/A · Big-stake notice, amended | Nov 13, 2025 | Big-stake notice | SEC |
| 8-K · Current report | Nov 5, 2025 | Results | SEC |
This page holds 200 of 803 filings. Open Filings
Cap table
Built by 6ix from Dyne Therapeutics, Inc.’s releases · as of Nov 17, 2026
- Common shares
- 187,386,963
- Fully diluted
- 187,667,163
Fully diluted
| Line | Shares | As of |
|---|---|---|
| Common shares | 187,386,963 | |
| Options and RSUs | 280,200 | Nov 17, 2026 |
Warrants and options
| Lot |
|---|
| Stock options · expire about Nov 2036 |
| RSUs · expiry not stated |
Share count over time
| Count | Shares |
|---|---|
| Nov 22, 2026 | 187,386,963 |
People
6ix reads each seat by machine from the page it links to, and can misread one.
| Person | Seat |
|---|---|
| Edward Hurwitz Other companies: MacroGenics, Inc. (Director · Since at least Oct 9, 2013); Turmeric Acquisition Corp (Chief Financial Officer · Oct 15, 2020 – Oct 15, 2020 · Past); Tvardi Therapeutics, Inc. (Director · Jan 30, 2014 – Feb 5, 2014 · Past); Sunesis Pharmaceuticals Inc (Director · Apr 3, 2009 – Jun 28, 2013 · Past) | Director · Since at least Jul 31, 2020 |
| Jason Rhodes Other companies: Generation Bio Co (Director · Since at least Jun 11, 2020); Disc Medicine, Inc. (Director · Feb 5, 2021 – Oct 4, 2021 · Past); Replimune Group, Inc. (Director · Jul 19, 2018 – Apr 1, 2022 · Past); Epizyme Inc (President, CFO and Treasurer · May 30, 2013 – Sep 22, 2014 · Past) | Chairman · Since at least Sep 16, 2020 |
| John Cox Other companies: Sigilon Therapeutics Inc (Director · Dec 3, 2020 – Aug 11, 2023 · Past); Bioverativ Inc (Chief Executive Officer, Director · Dec 22, 2016 – Mar 8, 2018 · Past); Repligen Corporation (Director · Nov 15, 2013 – Mar 24, 2020 · Past); Biogen Inc. (EVP Pharmaceutical Oper & Tech · Nov 1, 2011 – Apr 1, 2016 · Past) | President and Chief Executive Officer · Since at least Mar 25, 2024 |
| Joshua Brumm Other companies: Crescent Biopharma, Inc. (Chief Executive Officer · Since at least Jun 13, 2025); Kaleido Biosciences, Inc. (See Remarks · Feb 27, 2019 – Mar 4, 2019 · Past); Aravive Inc (COO and CFO · Nov 12, 2015 – Oct 19, 2017 · Past) | CEO & President, Director · Sep 16, 2020 – Mar 8, 2024 · Past |
| Erick J. Lucera Other companies: SAB Biotherapeutics, Inc. (Director · Since at least Dec 16, 2025); Beyond Air, Inc. (Director · Since at least Nov 4, 2025) | Chief Financial Officer · Since at least Mar 31, 2025 |
| Lucia Celona Other companies: Apellis Pharmaceuticals, Inc. (See Remarks · Aug 5, 2019 – Feb 10, 2020 · Past); Bioverativ Inc (EVP, HR & Corp Commun. Officer · Dec 22, 2016 – Mar 8, 2018 · Past) | Chief Human Resources Officer · Since at least Nov 5, 2026 |
| Richard William Scalzo Other companies: Crescent Biopharma, Inc. (Chief Financial Officer · Since at least Jun 13, 2025); Kaleido Biosciences, Inc. (Principal Accounting Officer · Oct 11, 2019 – Oct 11, 2019 · Past) | SVP, Head of Finance & Admin. · Sep 16, 2020 – Mar 11, 2025 · Past |
| Brian S. Posner Other companies: Arch Capital Group Ltd. (Director · Since at least May 5, 2026) | Board Member · Since at least Oct 2, 2025 |
| David Lubner Other companies: Crescent Biopharma, Inc. (Director · Since at least Jul 31, 2025) | Board Member · Since at least Apr 28, 2026 |
| Douglas Kerr Other companies: Generation Bio Co (CHIEF MEDICAL OFFICER · Jun 11, 2020 – Jan 29, 2024 · Past) | Head of R&D and CMO · Since at least Sep 3, 2024 |
All 29 people
| Person | Seat |
|---|---|
| Vikram Karnani Other companies: Collegium Pharmaceutical, Inc. (PRESIDENT & CHIEF EXECUTIVE OFFICER · Since at least Nov 7, 2024) | Board Member · Since at least Dec 22, 2025 |
| Alessandro Martuscelli | Chief Legal Officer · Since at least Nov 5, 2026 |
| Axel Wiest | Senior Vice President, Head of Portfolio Strategy & Operations · Since at least Nov 5, 2026 |
| Barry Greene | Board Member · Since at least Jun 22, 2026 |
| Carlo Incerti | Board Member · Since at least Nov 5, 2026 |
| Catherine Stehman-Breen | Board Member · Since at least Nov 5, 2026 |
| Debra Feldman | Chief Regulatory Affairs Officer · Since at least Nov 5, 2026 |
| Dirk Kersten | Board Member · Since at least Apr 15, 2026 |
| Doug Kerr | Head of Research & Development and Chief Medical Officer · Since at least Sep 29, 2026 |
| Ed Hurwitz | Board Member · Since at least Nov 4, 2026 |
| James P. Bilotta | Chief Digital Information Officer · Since at least Nov 5, 2026 |
| Johanna Friedl-Naderer | Chief Commercial Officer · Since at least Jun 5, 2025 |
| José Juves | Chief Corporate & Patient Affairs Officer · Since at least Nov 5, 2026 |
| Monica Fay | Chief Medical Affairs Officer · Since at least Nov 5, 2026 |
| Oxana Beskrovnaya | Chief Innovation Officer · Since at least Sep 16, 2020 |
| Raj Manchanda | Chief Technical Officer · Since at least Nov 5, 2026 |
| Ranjan Batra | Chief Scientific Officer · Since at least Sep 3, 2026 |
| Romesh Subramanian | Chief Scientific Officer · Sep 16, 2020 – Sep 16, 2020 · Past |
| Vikram Ranade | Chief Business Officer · Since at least May 8, 2025 |
Log in to ask 6ix AI your own questions about Dyne Therapeutics, Inc.